期刊文献+

肠道细胞色素P450和P-糖蛋白对口服药物生物利用度的影响 被引量:6

Effects of Intestinal Cytochrome P450 and P-glycoprotein on Oral Drug Bioavailability
下载PDF
导出
摘要 目的综述肠道细胞色素P450和P-糖蛋白(P-gp)对口服药物生物利用度的影响,包括CYP450、Pgp的作用及CYP与Pgp的联合作用。方法收集、阅读并分析近十年来关于肠道细胞CYP450和Pgp影响口服药物生物利用度的文献。结果 CYP450和Pgp在胃肠道均具有高表达,且两者的底物具有显著的重叠性,所以肠道细胞CYP450对已吸收药物的生物转化作用和肠道细胞中Pgp对已吸收药物的主动外排作用是影响口服药物生物利用度的重要因素。结论肠道细胞CYP450和Pgp对药物的口服生物利用度具有重要影响。 Objective The effects of intestinal cytochrome P450(CYP450) and P-glycoprotein(P-gp) on oral drug bioavailability including the effects of CYP450,Pgp and the combined effects of them were rebiewed.Methods Collect,read and analyse literatures about the effects of intestinal CYP450 and Pgp on oral drug bioavailability.Results CYP450 and Pgp exhibited high expression in gastrointestinal tract.In addition,they possessed overlapping substrate specificities.Therefore,biotransformation of absorbed drug by intestinal CYP450 and active efflux by intestinal Pgp were the main factors affecting oral drug bioavailability.Conclusion Intestinal CYP450 and Pgp showed significant effect on oral drug bioavailability.
出处 《中国药事》 CAS 2011年第7期724-728,共5页 Chinese Pharmaceutical Affairs
关键词 口服药物生物利用度 细胞色素P450 P-糖蛋白 oral bioavailability cytochrome P450 P-glyco protein
  • 相关文献

参考文献30

  • 1Dreiseitel A, Schreier P, Oehme A, et al. Anthocyanins an their metabolites are weak inhibitors of cytochrome P450 3A[J].Molecular nutrition & food research, 2008, 52 (12) 1428-1433.
  • 2Zhang Q Y, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450 [J].Drug me- tabolism and disposition: the biological fate of chemicals, 1999, 27 (7):804-809.
  • 3谢珊珊,景欣悦,刘晓东.小肠CYP450酶在药物代谢中的作用[J].中国药科大学学报,2010,41(2):186-192. 被引量:11
  • 4Paine M F, Hart H L, Ludington S S, et al. The human in- testinal cytochrome P450 " pie" [J]. Drug metabolism and disposition: the biological fate of chemicals, 2006, 34 (5) : 880-886.
  • 5Bieche I, Narioz C, Asselah T, et al. Reverse transcriptase- PCR quantification of mRNA levels from cytochrome (CYP) 1, CYP2 and CYP3 families in 22 different human tissues [J]. Pharmaeogenetics and genomies, 2007, 17 (9): 731-742.
  • 6Wienkers L C, Heath T G. Predicting in vivo drug interac tions from in vitro drug discovery data[J].Nature reviews, 2005, 4 (10): 825-833.
  • 7Lapple F, von Richter O, Fromm M F, et al. Differential ex- pression and function of CYP2C isoforms in human intestine and liver [J]. Pharmacogenetics, 2003, 13 (9): 565-575.
  • 8Thelen K, Dressman J B. Cytochrome P450-mediated metab- olism in the human gut wall[J]. The Journal of pharmacy and pharmacology, 2009, 61 (5): 541-558.
  • 9Galetin A, Hinton L K, Burt H, et al. Maximal inhibition of intestinal firs-pass metabolism as a pragmatic indicator of in- testinal contribution to the drug-drug interactions for CYP3A4 cleared drugs [J ] . Current drug metabolism, 2007, 8 (7): 685-693.
  • 10Ogasawara A, Kume T, Kazama E. Effect of oral ketocon azole on intestinal first pass effect of midazolam and fexofe nadine in cynomolgus monkeys [J]. Drug metabolism and disposition: the biological fate of chemicals, 2007, 35 (3): 410-418.

二级参考文献105

共引文献37

同被引文献54

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部